Cosentyx snrdy 300MG dose-2PENML
Ended Awarded
- Contract number
- SPE2DB25FY8XA
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $74,162
Award facts
- Contract value 100% obligated
- $74,162.45 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $74,162.45 to AmerisourceBergen Drug Corp for the supply of Cosentyx (secukinumab) 300mg dose in 2-pen/ml configuration. The contract was awarded on August 5, 2025, with an ultimate completion date of August 6, 2025, under a firm fixed-price arrangement with no set-aside designation. Performance will be executed from AmerisourceBergen's location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.999 billion prime vendor agreement that extends through December 2026 and serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs.
AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, is a critical federal vendor for the Defense Health Agency and military medical supply chains. The company's extensive federal procurement portfolio demonstrates competitive capability across multiple therapeutic domains, including specialty medications, biologics, and medical supplies. This delivery order for Cosentyx—a biologic immunosuppressant used to treat autoimmune conditions—reflects AmerisourceBergen's ongoing role in meeting Department of Defense pharmaceutical requirements through the DLA Medical Supply Chain network serving active-duty personnel, military beneficiaries, and federal healthcare systems.
Quick answers
Who was awarded contract SPE2DB25FY8XA?
SPE2DB25FY8XA was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on August 5, 2025.
How much is contract SPE2DB25FY8XA worth?
The government has obligated $74,162 on SPE2DB25FY8XA.
Is contract SPE2DB25FY8XA an order under another contract?
Yes. SPE2DB25FY8XA is a delivery order under SPE2DB22D3301, an indefinite delivery contract.
Was contract SPE2DB25FY8XA competed?
The extent of competition for SPE2DB25FY8XA was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award